A practical reference on mass spectrometry: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-06 and is reviewed periodically as new material appears.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Solid material is generally held at -20 °C or colder, while reconstituted solutions are kept at 2-8 °C and used within a short window. Buffers that maintain a slightly acidic to neutral pH tend to improve short-term peptide stability. Repeated warming and cooling of stock solutions promotes aggregation and should be avoided. Container closures should remain intact, since adsorption to some plastics can reduce the amount of peptide in solution.
Identity and purity are established with reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatographic profiles reveal related impurities, truncated sequences, and oxidation products, while mass measurement confirms the expected molecular mass. Purity values for research material are typically reported as a percentage by peak area. Reference standards help calibrate retention behavior across instruments. Independent laboratories emphasize method suitability because results depend heavily on column chemistry, gradient, and detection wavelength. Batch-to-batch comparison relies on the same validated method.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Stability depends strongly on physical state. Dry powder is comparatively robust when held at -20 °C or below, desiccated and shielded from light; under those conditions degradation is slow and measured over years. Once dissolved, the peptide becomes far more vulnerable: backbone hydrolysis, oxidation of susceptible residues and aggregation all proceed faster in solution, and the rates climb with temperature and with pH far from neutral. Refrigerated storage at 2–8 °C extends usable life for short periods, and repeated freeze–thaw cycles are best avoided.
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
=== Complications === Among the complications discussed above, women with anti-Ro/SS-A and anti-La/SS-B antibodies who become pregnant have an increased rate of neonatal lupus erythematosus with congenital heart block requiring a pacemaker. Type I cryoglobulinemia is a known complication of Sjögren's disease. Sjögren's disease can affect such organs as the liver, pancreas, kidneys, lungs, and central nervous system.
About 20,000 protein-coding genes are expressed in human cells and almost 75% of these genes are expressed in the normal prostate. About 150 of these genes are more specifically expressed in the prostate, with about 20 genes being highly prostate specific. The corresponding specific proteins are expressed in the glandular and secretory cells of the prostatic gland and have functions that are important for the characteristics of semen, including prostate-specific proteins, such as the prostate specific antigen (PSA), and the prostatic acid phosphatase.
The lotus is often confused with the true water lilies of the genus Nymphaea, in particular N. caerulea, the "blue lotus". In fact, several older systems, such as the Bentham & Hooker system (which is widely used in the Indian subcontinent), refer to the lotus by its old synonym, Nymphaea nelumbo. While all modern plant taxonomy systems agree that this species belongs in the genus Nelumbo, the systems disagree as to which family Nelumbo should be placed in or whether the genus should belong in its own unique family and order. According to the APG IV system, N. nucifera, N. lutea, and their extinct relatives belong in Proteales with the protea flowers due to genetic comparisons. Older systems, such as the Cronquist system, place N. nucifera and its relatives in the order Nymphaeles based on anatomical similarities. According to the APG IV classification, the closest relatives of Nelumbo include the sycamores (Platanaceae).
Current evidence suggests that dinosaur average size varied through the Triassic, Early Jurassic, Late Jurassic and Cretaceous. Predatory theropod dinosaurs, which occupied most terrestrial carnivore niches during the Mesozoic, most often fall into the 100-to-1,000 kg (220-to-2,200 lb) category when sorted by estimated weight into categories based on order of magnitude, whereas recent predatory carnivoran mammals peak in the 10-to-100 kg (22-to-220 lb) category. The mode of Mesozoic dinosaur body masses is between 1 and 10 metric tons (1.1 and 11.0 short tons). This contrasts sharply with the average size of Cenozoic mammals, estimated by the National Museum of Natural History as about 2 to 5 kg (4.4 to 11.0 lb). The sauropods were the largest and heaviest dinosaurs. For much of the dinosaur era, the smallest sauropods were larger than anything else in their habitat, and the largest was an order of magnitude more massive than anything else that has since walked the Earth. Giant prehistoric mammals such as Paraceratherium (the largest land mammal ever) were dwarfed by the giant sauropods, and only modern whales approach or surpass them in size. There are several proposed advantages for the large size of sauropods, including protection from predation, reduction of energy use, and longevity, but it may be that the most important advantage was dietary. Large animals are more efficient at digestion than small animals, because food spends more time in their digestive systems. This also permits them to subsist on food with lower nutritive value than smaller animals.
Sources: en.wikipedia.org
The Christian New Testament notes that some people thought that Jesus was, in some sense, Elijah, but it also makes clear that John the Baptist is "the Elijah" who was promised to come in Malachi 3:1; 4:5. According to accounts in all three of the Synoptic Gospels, Elijah appeared with Moses during the Transfiguration of Jesus. In Western Christianity, Elijah is commemorated as a saint with a feast day on 20 July by the Roman Catholic Church and the Lutheran Church–Missouri Synod. Catholics believe that he was unmarried and celibate. In the Eastern Orthodox Church and those Eastern Catholic Churches which follow the Byzantine Rite, he is commemorated on the same date (in the 21st century, Julian Calendar 20 July corresponds to Gregorian Calendar 2 August). He is greatly revered among the Orthodox as a model of the contemplative life. He is also commemorated on the Orthodox liturgical calendar on the Sunday of the Holy Fathers (the Sunday before the Nativity of the Lord). John the Baptist is also known as John the Forerunner in Christianity, John the Immerser in some Baptist Christian traditions, He is considered to be a prophet of God by all of these faiths, and is honoured as a saint in many Christian denominations. According to the New Testament, John anticipated a messianic figure greater than himself, and the Gospels portray John as the precursor or forerunner of Jesus, since John announces Jesus' coming and prepares the people for Jesus' ministry.
During cell division, a single cell, the mother cell divides into two daughter cells. This leads to the growth of tissue in multicellular organisms. Prokaryotic cells divide by binary fission, while eukaryotic cells usually undergo a process of nuclear division, called mitosis, followed by division of the cell, called cytokinesis. A diploid cell may undergo meiosis to produce haploid cells, usually four. Haploid cells serve as gametes in multicellular organisms, fusing to form new diploid cells. DNA replication, or the process of duplicating a cell's genome, always happens when a cell divides through mitosis or binary fission. This occurs during the S (synthesis) phase of the cell cycle. In meiosis, the DNA is replicated only once, while the cell divides twice. DNA replication only occurs before meiosis I. DNA replication does not occur when the cells divide the second time, in meiosis II. Replication, like all cellular activities, requires specialized proteins.
=== Biscuits company === In 1938, Lyons purchased the Bee Bee Biscuit Company, which manufactured biscuits from its factories in Blackpool. Six years later, Lyons changed the company's name to Symbol Biscuits Ltd. and began selling biscuits under the Symbol and Lyons brand names: one of their innovations was Maryland Cookies in 1956. In 1990, Lyons changed the Symbol Biscuits name to Lyons Biscuits Ltd.
Today this has resulted in the creation of the modern taco, burrito, and enchilada. Tug of war – the Iroquois claim tug of war was once related to a sort of celebratory ritual they used to practice. The Mohave people occasionally used tug-of-war matches as means of settling disputes. Turkey – approximately 2,000 years ago, ancient Mesoamericans domesticated the turkey during the Late Preclassic period—from 300 BCE to 100 CE.
=== EC 2.7.8: Transferases for other substituted phosphate groups === EC 2.7.8.1: diacylglycerol ethanolaminephosphotransferase EC 2.7.8.2: diacylglycerol cholinephosphotransferase EC 2.7.8.3: ceramide cholinephosphotransferase EC 2.7.8.4: serine ethanolaminephosphotransferase EC 2.7.8.5: CDP-diacylglycerol—glycerol-3-phosphate 1-phosphatidyltransferase EC 2.7.8.6: undecaprenyl-phosphate galactose phosphotransferase EC 2.7.8.7: holo-[acyl-carrier-protein] synthase EC 2.7.8.8: CDP-diacylglycerol—serine O-phosphatidyltransferase EC 2.7.8.9: phosphomannan mannosephosphotransferase EC 2.7.8.10: sphingosine cholinephosphotransferase EC 2.7.8.11: CDP-diacylglycerol—inositol 3-phosphatidyltransferase EC 2.7.8.12: CDP-glycerol glycerophosphotransferase EC 2.7.8.13: phospho-N-acetylmuramoyl-pentapeptide-transferase EC 2.7.8.14: CDP-ribitol ribitolphosphotransferase EC 2.7.8.15: UDP-N-acetylglucosamine—dolichyl-phosphate N-acetylglucosaminephosphotransferase EC 2.7.8.16: deleted, now included with EC 2.7.8.2 diacylglycerol cholinephosphotransferase EC 2.7.8.17: UDP-N-acetylglucosamine—lysosomal-enzyme N-acetylglucosaminephosphotransferase EC 2.7.8.18: UDP-galactose—UDP-N-acetylglucosamine galactose phosphotransferase EC 2.7.8.19: UDP-glucose—glycoprotein glucose phosphotransferase EC 2.7.8.20: phosphatidylglycerol—membrane-oligosaccharide glycerophosphotransferase EC 2.7.8.21: membrane-oligosaccharide glycerophosphotransferase EC 2.7.8.22: 1-alkenyl-2-acylglycerol choline phosphotransferase EC 2.7.8.23: carboxyvinyl-carboxyphosphonate phosphorylmutase EC 2.7.8.24: CDP-diacylglycerol—choline O-phosphatidyltransferase EC 2.7.8.25: Now EC 2.4.2.52, triphosphoribosyl-dephospho-CoA synthase EC 2.7.8.26: adenosylcobinamide-GDP ribazoletransferase EC 2.7.8.27: sphingomyelin synthase EC 2.7.8.28: 2-phospho-L-lactate transferase EC 2.7.8.29: L-serine-phosphatidylethanolamine phosphatidyltransferase EC 2.7.8.30: Now EC 2.4.2.53, undecaprenyl-phosphate 4-deoxy-4-formamido-L-arabinose transferase EC 2.7.8.31: undecaprenyl-phosphate glucose phosphotransferase EC 2.7.8.32: 3-O-α-D-mannopyranosyl-α-D-mannopyranose xylosylphosphotransferase EC 2.7.8.33: UDP-N-acetylglucosamine—undecaprenyl-phosphate N-acetylglucosaminephosphotransferase EC 2.7.8.34: CDP-L-myo-inositol myo-inositolphosphotransferase EC 2.7.8.35: UDP-N-acetylglucosamine—decaprenyl-phosphate N-acetylglucosaminephosphotransferase EC 2.7.8.36: undecaprenyl phosphate N,N′-diacetylbacillosamine 1-phosphate transferase EC 2.7.8.37: α-D-ribose 1-methylphosphonate 5-triphosphate synthase EC 2.7.8.38: archaetidylserine synthase EC 2.7.8.39: archaetidylinositol phosphate synthase EC 2.7.8.40: UDP-N-acetylgalactosamine-undecaprenyl-phosphate N-acetylgalactosaminephosphotransferase EC 2.7.8.41: cardiolipin synthase (CMP-forming) EC 2.7.8.42: Kdo2-lipid A phosphoethanolamine 7′′-transferase EC 2.7.8.43: lipid A phosphoethanolamine transferase EC 2.7.8.44: teichoic acid glycerol-phosphate primase EC 2.7.8.45: teichoic acid glycerol-phosphate transferase EC 2.7.8.46: teichoic acid ribitol-phosphate primase EC 2.7.8.47: teichoic acid ribitol-phosphate polymerase
Sources: en.wikipedia.org
While in New York, Eric cheats on his wife with Newman’s widow Holly. When Pierpoint plans to merge its London and New York desks, Eric and Harper engineer a survival pitch that preserves London by sacrificing Rishi and DVD. After Harper becomes implicated in insider trading, Eric protects her by exposing her forged transcripts instead, getting her fired. In series 3, Eric leads the merged CPS/FX desk. Separated from Candice and newly sober with Kenny’s help, he is promoted to partner but ordered by Adler to fire a senior colleague, leading him to impulsively fire Kenny. Eric uncovers that the debt Pierpoint issued to fund its pivot to ESG is nearing maturity amid failed IPOs and realizes the firm is close to collapse. Adler later reveals to Eric he is dying of a brain tumor. The night before the IPO, Eric does coke with Yasmin and her lawyer, asking Yasmin to leave so he can have sex with the lawyer. Learning that Harper is shorting Pierpoint using ESG data obtained from Yasmin, Eric fires Yasmin after images of her father’s drowned body leak. As Pierpoint’s debt crisis becomes public and its stock collapses, Eric ultimately exploits Adler's illness to sabotage him during acquisition talks and engineers Pierpoint’s sale to Egyptian sovereign wealth fund Al-Mi’raj via internal connections. Though the acquisition costs Eric his job due to the closure of the London trading floor, he leaves with a substantial severance, personally informing his team and calling Harper to wish her well.
== Regulation == While infant formula is highly regulated in many countries, baby bottles are not. Only the materials of the teat and bottle itself are specifically regulated in some countries (e.g. British Standards BS 7368:1990 "Specification for babies' elastomeric feeding bottle teats"). In the US, the Food and Drug Administration (FDA) regulates teats and the bottle materials. In 1985 the FDA restricted allowable levels of nitrosamines (many of which are carcinogens) released from bottle teats. Tests of bottle nipples available in the US, Singapore, West Germany, England, Japan and Korea suggest that levels of nitrosamines in most rubber baby bottle teats are within recommended standards. Another chemical that has been regulated is Bisphenol A (BPA), described as an endocrine disruptor in 1991. Ongoing research into the possible effects of BPA at levels of exposure far below the U.S. government's BPA safety standards has led to concerns about the safety of plastics, including baby bottles. A 1999 Consumer Reports study showed that some polycarbonate baby bottles released unsafe amounts of BPA. Concerns about BPA have been supported by further work. (Research into the effects of BPA has frequently been hotly contested and controversial and issues have been raised over research biases due to industry funding and conflicts of interest due to close ties between government consultants and BPA manufacturers.) One result has been proposals to change the testing paradigm for assessment of endocrine-disrupting chemicals.
Lesch–Nyhan syndrome (LNS) is a rare genetic disorder caused by a deficiency of the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT). This deficiency occurs due to mutations in the HPRT1 gene located on the X chromosome. LNS affects about 1 in 380,000 live births. The disorder was first recognized and clinically characterized by American medical student Michael Lesch and his mentor, pediatrician William Nyhan, at Johns Hopkins. The HGPRT deficiency causes a build-up of uric acid in all body fluids. The combination of increased synthesis and decreased utilization of purines leads to high levels of uric acid production. This results in both high levels of uric acid in the blood and urine, associated with severe gout and kidney problems. Neurological signs include poor muscle control and moderate intellectual disability. These complications usually appear in the first year of life. Beginning in the second year of life, a particularly striking feature of LNS is self-mutilating behaviors, characterized by lip and finger biting. Neurological symptoms include facial grimacing, involuntary writhing, and repetitive movements of the arms and legs similar to those seen in Huntington's disease. The cause of the neurological abnormalities remains unknown. Because a lack of HGPRT causes the body to poorly utilize vitamin B12, some males may develop megaloblastic anemia.
In patients with mild, moderate, or severe hepatic impairment, the mean AUC values for total ezetimibe are increased about 1.7-fold, 3-to-4-fold, and 5-to-6-fold, respectively, compared to healthy subjects.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
Solid powder is held frozen at -20 °C or below in a desiccated container. Reconstituted solutions are refrigerated and used within a limited period.